XyloCor Therapeutics Achieves Target Enrollment in Phase II EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XyloCor Therapeutics, announced it has achieved enrollment of target number of subjects in the Phase II portion of its ongoing Phase I/II clinical trial for refractory angina.